When: Confirmed breakout above $100 on volume >8M for two consecutive sessions

Then: Trail remaining position toward $100+

HOLD

• Current entry price of $93.35 is unfavorable given RSI near overbought (68.5) and price within $2 of upper Bollinger Band
• Textbook bullish MA configuration does not justify entry timing - this constitutes momentum chasing
• RSI bearish divergence confirmed: price made higher high at $94.13 while RSI made lower high
• EPS trajectory is choppy, not clean: quarterly figures of 0.82, 0.81, 1.07, 0.89, 0.96
• TTM EPS is $3.73; current valuation implies forward EPS of $6.41, requiring 72% growth from current run-rate
• If forward EPS comes in at $5 instead of $6.41, multiple expands from 14.6 to 18+ - significant re-rating risk
• MACD histogram peaked on August 19 and has been declining since
• The $88 million hernia mesh verdict is a federal jury record-setting bellwether trial template for thousands of cases
• Medtronic balance sheet has $52.7 billion goodwill and negative tangible book value of negative $3.27 billion
• Stop at $89 sits only $0.36 above 200 SMA at $88.64 - inadequate buffer with high stop-out probability
• ATR is $2.15 normally but can expand to $4-5 around earnings binary catalyst
• Beta of 0.57 calculated over long horizons; realized volatility around events is 2-3x higher
• Affera PFA platform ranks third behind Boston Scientific and Johnson & Johnson in the category
• 3.12% dividend yield not exceptional when T-bills yielding 4%+
• Conservative framework: hold at current levels, add only on confirmed test of 200 SMA support zone at $88.50
• Proposed stop loss placement creates cascade risk if price slices through both $89 and 200 SMA simultaneously

→ vs aggressive: Entry at $93.35 with RSI near overbought and price near upper Bollinger Band is momentum chasing, not disciplined risk management

→ vs aggressive: RSI divergence (price $94.13 vs lower RSI high) is a yellow flag requiring reduced exposure, not a continuation signal to add

→ vs aggressive: EPS trajectory is choppy (0.82, 0.81, 1.07, 0.89, 0.96) requiring 72% growth assumption that is not supported by reported numbers; TTM EPS only $3.73 vs implied forward $6.41

→ vs aggressive: Calling $88 million bellwether verdict '0.07% of market cap' is malpractice-level assessment given it is a record-setting federal jury verdict setting template for thousands of cases with potential punitive damages multiplier

→ vs aggressive: Stop at $89 is only $0.36 above 200 SMA at $88.64 - inadequate buffer where a daily close below $89 invalidates entire bull thesis and triggers cascade selling

→ vs aggressive: ATR of $2.15 can expand to $4-5 around earnings, making the 'tight stop' proposal vulnerable to noise clipping; beta of 0.57 understates event-period realized volatility by 2-3x

→ vs aggressive: Defensive rotation is a relative-trade story, not absolute-return story; 3.12% yield is marginal vs 4%+ T-bills; macro tailwind is neutral-to-supportive and largely already priced in

→ vs aggressive: Affera PFA platform is third to market behind Boston Scientific and J&J - building bull case on third-place market share potential is speculative, not transformational

HOLD; Conditional buy at $91.20-$91.50 with stop at $87.50; Trim 25% at $94.80, 25% at $97.50, hold 50% with trailing stop

• HOLD current position; do not add above $92 or chase at $93.35
• Set conditional buy order at $91.20 to $91.50 (10 EMA zone)
• Hard stop at $87.50 (below 200 SMA at $88.64) to account for earnings volatility
• Risk per share from add zone: $3.70 to $4.00
• Aggressive analyst's $89 stop is too tight given $2.15 ATR and earnings catalyst risk
• Conservative analyst's $88.50 target is too far; shallow pullbacks often find support at 10 EMA
• 200 SMA has flipped to support at $88.64; 50 SMA accelerating at $84.21
• MACD crossed bullish in July; 280 basis points margin expansion improving operating momentum
• $4.6 billion trailing free cash flow and current ratio over 2 indicate balance sheet resilience
• Forward multiple of 14.6x implies ~$6.40 EPS vs TTM $3.73—a step-change requiring delivery
• Trim 25% at upper Bollinger ($94.80), 25% at supply zone ($97.50), let 50% ride with trailing stop at rising 10 EMA
• Litigation is a watching item, not sizing item; keep position size modest until punitive damages quantified
• Earnings ahead is a binary catalyst; win probability for aggressive analyst's setup closer to 55% than 70%

→ vs aggressive: The $89 stop sits on top of the 200 SMA at $88.64 and will likely get clipped by routine post-earnings volatility even if the trend holds; adjusted for the earnings haircut, expected value is much closer to neutral than claimed

→ vs aggressive: The 14.6x forward multiple pricing in ~$6.40 EPS against TTM $3.73 is a step-change, not a continuation of the recovery—if forward earnings come in at $5.50 instead, the multiple expands to 17x and the stock sells off regardless of moving averages

→ vs aggressive: Dismissal of hernia mesh litigation as a rounding error conflates 'small in dollars today' with 'small in stock-price impact over 12-24 months'; bellwether trials set precedent for punitive damages scaling

→ vs conservative: Waiting for $88.50 to $90.00 before adding is contrarian dressed as discipline; the 200 SMA has flipped to support and in trending markets you often get shallow dips at the 10 EMA rather than full retests of major support

→ vs conservative: Overstates litigation tail risk relative to the data: MDT has 49-year dividend track record, $4.6B FCF, current ratio over 2, declining net debt—the balance sheet is not fragile operationally

→ vs conservative: The Fed pause being 'largely priced in' cuts against his own thesis—if the macro tailwind is fully discounted, it's also not a headwind, removing the case for patience and waiting for a $5 pullback